ArticlePLoS neglected tropical diseases2026
Immunogenicity of two representative American consensus scorpion neurotoxins from the genera Tityus and Centruroides.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two consensus scorpion toxins derived from venoms of the genera Centruroides (NATx, North America), and Tityus (SATx, South America) were rationally designed and recombinantly expressed in Escherichia coli Origami. Both recombinant proteins were produced as inclusion bodies and subsequently purified and refolded in vitro to obtain biologically active isoforms. The expression yields were approximately 1 mg/L for rNATx and 0.5 mg/L for rSATx. Structural characterization by circular dichroism spectroscopy revealed that rNATx and rSATx exhibited folding patterns typical of scorpion β-toxins. The purified recombinant toxins were used as immunogens to raise polyclonal antibodies in New Zealand rabbits. The resulting antisera were evaluated for their capacity to neutralize isolated toxins and whole scorpion venoms. rNATx elicited a stronger immune response and showed superior immunogenicity compared to rSATx. Notably, 1-1.5 mg of anti-rNATx antibodies were sufficient to neutralize up to 3LD50 of venoms from the most medically relevant Centruroides species in México. On the other hand, approximately 20 mg of anti-rSATx antibodies were required to neutralize only 2LD50 of Tityus venoms. Additionally, T-cell subsets quantified by flow cytometry showed that rNATx is more immunogenic and probably confers improved antivenom efficacy, highlighting its potential application in the development of broad-spectrum antivenoms against scorpion envenomation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.